Change point analyses in prodromal Alzheimer’s disease
Change point analysis can reveal when a biomarker starts to diverge from the pattern of normal aging. This paper analyzes several biomarkers from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) to estimate the sequence and timing of their change points relative to a subsequent clinical diagno...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2020-12-01
|
| Series: | Biomarkers in Neuropsychiatry |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666144620300186 |
| _version_ | 1818408333550288896 |
|---|---|
| author | Alvin H. Bachman Babak A. Ardekani |
| author_facet | Alvin H. Bachman Babak A. Ardekani |
| author_sort | Alvin H. Bachman |
| collection | DOAJ |
| description | Change point analysis can reveal when a biomarker starts to diverge from the pattern of normal aging. This paper analyzes several biomarkers from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) to estimate the sequence and timing of their change points relative to a subsequent clinical diagnosis of mild cognitive impairment (MCI) in subjects initially considered cognitively normal (CN). Data on 379 stable CN (sCN) and 98 progressive CN (pCN) subjects who progressed to an MCI diagnosis were used. Linear mixed-effects change point models were used to estimate when various biomarkers in pCN started to diverge from rates expected in normal aging. Our results indicate that in pCN, hippocampal atrophy rate diverges from normal aging 12.4 (±2.8) years before MCI diagnosis, followed by ventricular volume expansion and decrease in Rey Auditory Verbal Learning Test of immediate recall scores about 5 years later. Glucose metabolism decrease begins about 5 (±1.3) years before diagnosis, followed by deterioration in other cognitive test scores. Planned AD interventions should note that irreversible changes such as atrophy may occur a decade before possible diagnosis of MCI. |
| first_indexed | 2024-12-14T09:42:04Z |
| format | Article |
| id | doaj.art-de3b023537ea44838f0567f908a88cf0 |
| institution | Directory Open Access Journal |
| issn | 2666-1446 |
| language | English |
| last_indexed | 2024-12-14T09:42:04Z |
| publishDate | 2020-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Biomarkers in Neuropsychiatry |
| spelling | doaj.art-de3b023537ea44838f0567f908a88cf02022-12-21T23:07:45ZengElsevierBiomarkers in Neuropsychiatry2666-14462020-12-013100028Change point analyses in prodromal Alzheimer’s diseaseAlvin H. Bachman0Babak A. Ardekani1The Nathan S. Kline Institute for Psychiatric Research, Orangeburg, NY, USAThe Nathan S. Kline Institute for Psychiatric Research, Orangeburg, NY, USA; Department of Psychiatry, New York University School of Medicine, New York, NY, USA; Corresponding author at: Center for Brain Imaging and Neuromodulation, The Nathan S. Kline Institute for Psychiatric Research, 140 Old Orangeburg Rd, Orangeburg, NY, 10962, USA.Change point analysis can reveal when a biomarker starts to diverge from the pattern of normal aging. This paper analyzes several biomarkers from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) to estimate the sequence and timing of their change points relative to a subsequent clinical diagnosis of mild cognitive impairment (MCI) in subjects initially considered cognitively normal (CN). Data on 379 stable CN (sCN) and 98 progressive CN (pCN) subjects who progressed to an MCI diagnosis were used. Linear mixed-effects change point models were used to estimate when various biomarkers in pCN started to diverge from rates expected in normal aging. Our results indicate that in pCN, hippocampal atrophy rate diverges from normal aging 12.4 (±2.8) years before MCI diagnosis, followed by ventricular volume expansion and decrease in Rey Auditory Verbal Learning Test of immediate recall scores about 5 years later. Glucose metabolism decrease begins about 5 (±1.3) years before diagnosis, followed by deterioration in other cognitive test scores. Planned AD interventions should note that irreversible changes such as atrophy may occur a decade before possible diagnosis of MCI.http://www.sciencedirect.com/science/article/pii/S2666144620300186Change PointMCIADNIAlzheimer’s diseaseHippocampusVentricles |
| spellingShingle | Alvin H. Bachman Babak A. Ardekani Change point analyses in prodromal Alzheimer’s disease Biomarkers in Neuropsychiatry Change Point MCI ADNI Alzheimer’s disease Hippocampus Ventricles |
| title | Change point analyses in prodromal Alzheimer’s disease |
| title_full | Change point analyses in prodromal Alzheimer’s disease |
| title_fullStr | Change point analyses in prodromal Alzheimer’s disease |
| title_full_unstemmed | Change point analyses in prodromal Alzheimer’s disease |
| title_short | Change point analyses in prodromal Alzheimer’s disease |
| title_sort | change point analyses in prodromal alzheimer s disease |
| topic | Change Point MCI ADNI Alzheimer’s disease Hippocampus Ventricles |
| url | http://www.sciencedirect.com/science/article/pii/S2666144620300186 |
| work_keys_str_mv | AT alvinhbachman changepointanalysesinprodromalalzheimersdisease AT babakaardekani changepointanalysesinprodromalalzheimersdisease |